Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.

By R. Amado, M. Wolf, M. Peeters, E. Van Cutsem, S. Siena, Daniel J. Freeman, T. Juan, R. Sikorski, S. Suggs, R. Radinsky and 2 more. Journal of Clinical Oncology, 2008

2,970 citations recorded by the source corpus.

Subfields: Immunology

View Paper: https://www.semanticscholar.org/paper/40fe829160ed54bc081d9ddc836f56ed75ea0370

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. J. Wolchok
2. René Bernards
3. Lloyd J. Old
4. Robert Schreiber

Citations in the corpus

• Systems Pharmacology: Network Analysis to Identify Multiscale Mechanisms of Drug Action (2012, background): “Panitumumab k-RAS (83) Requirement of wild-type k-RAS for drug efficacy”
• Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer (2019, background): “(IRI +) CET [206–208] or (IRI +) PANI [209, 210] Pembro (see comment 10) [202]”
• A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). (2015, neutral): “59) 2 [108]”
• Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. (2010, background): “G13D-mutated).(19-22) The objective response rate in unselected patients was 10.”
• Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2014, background): “The panitumumab trial did not show a survival difference due to the cross-over design of the trial [31, 32].”